A cure for cancer could be on the horizon in the next decade, according to experts.During the WSJ Leadership Institute CEO Summit in London last week, Johnson & Johnson Chairman and CEO Joaquin Duato reflected on the pharmaceutical company’s projections on the future of cancer treatment.In the next 10 years, the goal is to "try to eliminate cancer," Duato shared.NEW CANCER VACCINE DELIVERS STUNNING RESULT AGAINST ONE OF THE DEADLIEST SKIN CANCERS"That’s a high goal, and we are already making significant progress in certain cancers," he said.Duato used multiple myeloma as an example, noting that the life expectancy is currently 10 years, when it was previously "only single years."Joaquin Duato, chairman and CEO of Johnson and Johnson, speaks at the Punchbowl News Conference at Union Station on March 10, 2026, in Washington, DC.(Heather Diehl/Getty Images)"We have treatments now that utilize your own immune system to attack the cancer," he said at the summit.
"For patients who were already going into hospice, so they didn’t have any other alternative, they are [at] more than five years, with a single administration, in remission.That [is] spectacular."CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER"When patients see that, they cannot believe that because they have been coming to the hospital every week [for] a decade, having multiple therapies."The goal is to "try to eliminate cancer" in the next 10 years, the pharmaceutical executive said.
(iStock)According to Duato, Johnson & Johnson is working to understand the biology of cancer growth and to formulate new technologies to address it."It’s realistic to believe that we are going to cure certain cancers, and some others we’re going to turn into chronic diseases," he predicted.CLICK HERE FOR MORE HEALTH STORIES"Cancer is an important thing – I cannot think about anybody who has not been touched by cancer," he went on."But there are many other opportunities for us to actually advance science, to a...